Gilead unveils promising hep C, fatty liver data; setbacks elsewhere

(Reuters) - Gilead Sciences Inc on Thursday announced high cure rates across all types of hepatitis C in late stage studies testing a triple drug combination, and said another experimental drug showed promise in reducing liver scarring known as fibrosis in a midstage trial.